Filing Flows

Filing Flows › Companies › Cytek Biosciences › Cash flow

Cytek Biosciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.0M in Q3 2026 · −$13.5M over twelve months

Operating cash flow−$4.5M
Capital spending−$1.5M
Free cash flow−$6.0M
Cash conversion cycle285 days

Analysis

In Q3 2026, Cytek Biosciences generated −$4.5M of operating cash flow and spent $1.5M on capital projects, leaving free cash flow of −$6.0M. That is $1.4M less than in Q3 2025 (−$4.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$6.6M; the largest uses were other investing ($17.1M), capital spending ($6.9M), operating cash flow ($6.6M); besides operations, cash came from shares issued ($1.2M), other financing ($343K); the cash balance fell by $26.1M.

Operating cash flow was −$4.5M against net income of −$6.1M. The largest differences: deferred revenue +$18.5M, receivables −$10.1M, stock-based pay +$4.9M.

Its cash conversion cycle was 285 days (receivables 94 + inventory 219 − payables 28).

Free cash flow

Cytek Biosciences: free cash flow by quarterCytek Biosciences: free cash flow by quarter$1.1MQ4 2024−$974KQ1 2025−$1.5MQ2 2025−$4.6MQ3 2025−$1.8MQ4 2025−$4.9MQ1 2026−$849KQ2 2026−$6.0MQ3 2026
Operating cash flow less capital spending.
Cytek Biosciences: operating cash flow against capital spendingCytek Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending$2.0M$894KQ4 2024−$125K$849KQ1 2025$108K$1.6MQ2 2025−$3.9M$657KQ3 2025−$771K$1.0MQ4 2025−$2.7M$2.2MQ1 2026$1.4M$2.2MQ2 2026−$4.5M$1.5MQ3 2026
Latest (Q3 2026): Operating cash flow −$4.5M, Capital spending $1.5M.

Capital allocation, year by year

Cytek Biosciences: where the cash came from (up) and went (down), by fiscal yearCytek Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $4.6MFY2021: Shares issued $216MFY2021: Capital spending −$4.4MFY2021: Acquisitions −$17.0M$221MFY2021FY2022: Operating cash flow −$12.2MFY2022: Net borrowing $2.9MFY2022: Shares issued $1.2MFY2022: Capital spending −$9.7M$4.1MFY2022FY2023: Operating cash flow $5.3MFY2023: Shares issued $1.5MFY2023: Capital spending −$4.6MFY2023: Acquisitions −$44.9MFY2023: Buybacks −$44.2M$6.7MFY2023FY2024: Operating cash flow $25.4MFY2024: Net borrowing $4.2MFY2024: Shares issued $1.0MFY2024: Asset sales $288KFY2024: Capital spending −$3.5MFY2024: Acquisitions −$471KFY2024: Buybacks −$21.6M$30.9MFY2024FY2025: Operating cash flow −$4.7MFY2025: Net borrowing $837KFY2025: Shares issued $325KFY2025: Asset sales $252KFY2025: Capital spending −$4.1MFY2025: Buybacks −$15.1M$1.4MFY2025
Over these 5 years operating cash flow totalled $18.4M; the largest uses were buybacks ($80.8M) and acquisitions ($62.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$66.8M
Debtnone
Net cash$66.8M
Cash runway5.0 years

Cytek Biosciences is burning cash: its operations consume cash, a free cash flow of −$13.5M a year at the current rate against $66.8M of cash and investments: a runway of about 5.0 years before any new financing.

Where the cash came from and went

Cytek Biosciences: sources (+) and uses (−) of cash, Q3 2026Cytek Biosciences: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$6.7MOperating cash flow−$4.5MCapital spending−$1.5MNet borrowing (+) / repaid (−)−$1.3MShares issued$1.0MOther investing−$365KOther financing−$264KExchange rates$158KAsset & business sales$71K
Cytek Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Cytek Biosciences: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)$26.1MOther investing−$17.1MCapital spending−$6.9MOperating cash flow−$6.6MExchange rates$2.8MShares issued$1.2MOther financing$343KAsset & business sales$275KNet borrowing (+) / repaid (−)−$202KBuybacks$34K

From profit to cash

Cytek Biosciences: net income to operating cash flow, Q3 2026Cytek Biosciences: net income to operating cash flow, Q3 2026Net income−$6.1MDepreciation & amortization$2.1MStock-based pay$4.9MGains on disposals$41KOther non-cash$11KReceivables−$10.1MInventory−$222KPayables−$3.6MAccrued liabilities$4.3MDeferred revenue$18.5MPrepaid and other assets$3.1MOperating cash flow−$4.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20269421928285
Q2 20269623435296
Q1 202611719326284
Q4 20258815722223
Q3 20259918827260
Q2 202511119927282
Q1 202512518925289
Q4 20249117521245

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$4.5M−$1.5M——−$1.3M$1.0M$6.7M−$6.0M
Q2 2026$1.4M−$2.2M——−$1.6M$91K−$8.2M−$849K
Q1 2026−$2.7M−$2.2M——$4.2M$21K$25.2M−$4.9M
Q4 2025−$771K−$1.0M——−$1.5M$85K$2.4M−$1.8M
Q3 2025−$3.9M−$657K—$29K$1.9M$137K−$17.8M−$4.6M
Q2 2025$108K−$1.6M—−$4.5M$1.2M$64K$19.8M−$1.5M
Q1 2025−$125K−$849K—−$10.6M−$828K$39K$3.4M−$974K
Q4 2024$2.0M−$894K−$471K−$7.0M$2.6M$138K$63.6M$1.1M

Cytek Biosciences: income statement and cash flow

Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%. The chart follows the revenue to costs, profit and cash.

Cytek Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.